JP2015091874A - Composition for preventing or treating cervical cancer having human papillomavirus plasmodium and immunity enhancer - Google Patents

Abstract

PROBLEM TO BE SOLVED: To provide a composition for preventing or treating cervical cancer having human papillomavirus plasmodium and immunity enhancer.SOLUTION: A fusion protein comprising a fused polypeptide recombined to transform the 3-dimensional structure of E6 and E7, which are antigens of type 16 and 18 of human papillomavirus (HPV), a signal peptide for secreting this outside the cell, and an immunity enhancer peptide inside the individual can treat HPV-triggered tumors by inducing an immune reaction specific to HPV type 16 and 18 antigens.

Description

  The present invention relates to a composition for preventing or treating cervical cancer comprising a human papillomavirus variant and an immunopotentiator, and more particularly, human papillomavirus (HPV) type 16 and 18 antigens E6 and 18 A fusion polypeptide comprising a recombinant polypeptide modified so that the three-dimensional structure of E7 is modified, a signal peptide for secreting it outside the cell, and an intra-individual immunity enhancing peptide is specific to HPV types 16 and 18 antigens. It can induce an immune response and treat tumors induced by HPV.

  Cervical cancer is known to be a disease caused by infection of high-risk human papillomaviruses such as human papillomavirus (HPV), such as types 16 and 18, (zur Hausen, H et al. Biochem Biophys). Acta 1996, 1288; F55-F78, Mark H et al. J Natl Cancer Inst 1993, 85; 958-964). Among HPV proteins, E6 and E7 proteins play a major role in the development of cervical cancer, and 99% is confirmed to be expressed in the tumor organization of cervical cancer patients, producing vaccines for treating and preventing cervical cancer (Von Knebel Doeberitz et al. Int. J. Cancer 1992, 51; 831-834). In the case of E6, it binds to p53 known as a tumor suppressor protein, promotes the degradation of p53 and prevents the cell cycle from progressing to the apoptosis pathway, and E7 is a tumor suppressor retinoblast. Binds to and inactivates the cytoma protein pRb and promotes its degradation, allowing the cell cycle to proceed to S phase (Cobrinik et al., Trends Biochem Sci 1992, 17: 312- 5).

  However, in clinical experiments using nucleobase sequence compositions that co-express HPV16 E6 and E7 proteins for the treatment of cervical cancer, the therapeutic effect was minimal (Garcia F et al. Obstet Gynecol 2004, 103; 317-326). The result means that simply administering HPV antigen alone does not produce an antigen-specific immune response that is sufficient to treat or suppress cervical cancer.

  Therefore, a strategy for enhancing the immunogenicity of E6 and E7 and removing the oncogenic potential of the protein itself is essential for the treatment of cervical cancer.

zur Hausen, H et al. Biochem Biophys Acta 1996, 1288; F55-F78 Garcia F et al. Obstet Gynecol 2004, 103; 317-326

  An object of the present invention is to provide a novel fusion protein having enhanced immunogenicity while inhibiting the oncogenic ability of HPV E6 and E7 proteins per se in preventing or treating diseases caused by HPV, and coding for the same It is to provide a polynucleotide.

  Another object of the present invention is to provide a recombinant vector expressing the fusion protein, a host cell containing the vector, and a method for expressing the protein using the host cell.

  Still another object of the present invention is to provide a composition for preventing or treating a disease caused by HPV using the fusion protein.

  Still another object of the present invention is to provide a method for preventing or treating a disease caused by HPV using the above composition.

In order to achieve the above object, the present invention provides:
A fusion polypeptide having a modified three-dimensional structure of E6 and E7, having the amino acid sequence set forth in SEQ ID NO: 1 derived from human papillomavirus types 16 and 18;
A signal peptide for secretion of the polypeptide;
And a fusion protein comprising: an immunopotentiating peptide.

  The present invention also provides a polynucleotide encoding the fusion protein of the present invention.

  The present invention also provides a recombinant vector comprising a polynucleotide according to the present invention.

  The present invention also provides host cells transformed with the vectors of the present invention.

  The present invention also provides a method for culturing the transformed host cell of the present invention and expressing the fusion protein of the present invention.

  The present invention also provides an individual human papilloma comprising, as an active ingredient, one or more selected from the group consisting of the fusion protein of the present invention, a host cell transformed with a recombinant vector expressing the protein, and a disrupted product thereof. A composition for preventing or treating a disease caused by a virus is provided.

  The present invention also provides a method of preventing or treating a disease caused by a human papillomavirus in an individual, comprising administering to the individual an effective amount of the composition of the present invention.

  A fusion protein recombined so that the three-dimensional structure of E6 and E7 proteins derived from HPV types 16 and 18 of the present invention is modified, a signal peptide for secreting this extracellularly, and an intra-individual immunity enhancing peptide Fusion proteins so produced can induce high HPV type 16 and 18 antigen-specific immune responses and treat tumors induced by HPV.

It is a graph which shows HPV16 E6-specific CD8 ^<+> T cell response which appears through the treatment of GX-188E of this invention, after inject | pouring TC-1 which is a tumor cell line into mouse C57BL / 6 in an anticancer treatment model. It is a graph which shows HPV16 E7 specific CD8 ^<+> T cell response which appears through the treatment of GX-188E of this invention, after inject | pouring TC-1 which is a tumor cell line into mouse C57BL / 6 in an anticancer treatment model. It is a graph which shows the HPV18 E6-specific CD8 ^<+> T cell response which appears through the treatment of GX-188E of this invention, after inject | pouring TC-1 which is a tumor cell line into mouse C57BL / 6 in an anticancer treatment model. It is a graph which shows HPV18 E7 specific CD8 ^<+> T cell response which appears through the treatment of GX-188E of this invention, after inject | pouring TC-1 which is a tumor cell line into mouse C57BL / 6 in an anticancer treatment model. It is a graph which shows the anticancer effect which appears through the treatment of GX-188E of this invention, after inject | pouring TC-1 which is a tumor cell line into mouse C57BL / 6 subcutaneously in an anticancer treatment model.

The configuration of the present invention will be specifically described below.
The present invention relates to a fusion polypeptide having a modified three-dimensional structure of E6 and E7 having the amino acid sequence described in SEQ ID NO: 1 derived from human papillomavirus types 16 and 18;
A signal peptide for secretion of the polypeptide;
An immunopotentiating peptide; and a fusion protein comprising:

  The fusion protein of the invention can comprise a fusion polypeptide that has been recombined such that the three-dimensional structure of E6 and E7 from human papillomavirus types 16 and 18 is altered. More specifically, the fusion polypeptide comprises amino acids 1 to 85 of E6 protein derived from human papillomavirus type 16, amino acids 1 to 65 of E7 protein, amino acids 71 to 158 of E6 protein, and E7 protein. From amino acids 51 to 98, amino acids 1 to 85 of E6 protein derived from human papillomavirus type 18, amino acids 1 to 65 of E7 protein, amino acids 71 to 158 of E6 protein, amino acids 51 to E7 protein No. 105 is a fusion polypeptide linked.

  Most specifically, the fusion polypeptide can have the amino acid sequence set forth in SEQ ID NO: 1 in the sequence listing.

  The signal peptide is a peptide containing about 20 to 30 amino acids, and secretes a protein expressed in the cell, particularly a protein containing E6 and E7 fusion polypeptides to the outside of the cell. The nucleic acid sequence coding for this is referred to as a “secretory signal sequence”. Since the E6 and E7 fusion polypeptides of the present invention are proteins expressed in the nuclei of cells infected with viruses (nucleus protein), they are weak in themselves. Thus, the signal peptide expressed by the secretory signal sequence induces the secretion of E6 and E7 antigens whose three-dimensional structures are modified to the outside of the cell, thereby causing an antigen-specific humoral immune response (humalal). It can lead to an increase in immune response and cellular immune response.

  As the signal peptide, a signal peptide used in higher eukaryotic cells including mammals and the like can be used. For example, tPA, HSV gDs, or a secretion signal sequence of growth hormone can be used. More preferably, TPA (tissue plasminogen activation) can be used. Most preferably, it can have the amino acid sequence set forth in SEQ ID NO: 2.

  In addition, the immune enhancing peptide refers to a peptide that activates a cell (for example, a dendritic cell) related to an immune response to increase the immune response.

  As the immunopotentiating peptide, CD40 ligand, Flt3 ligand (fms-like tyrosine kinase 3 ligand), flagellin, OX40, or the like can be used. More preferably, Flt3 ligand can be used. The Flt3 ligand is a factor that induces proliferation and maturation of dendritic cells (DCs), and increases the immune response by the antigen and is fused with the tumor antigen. Can show an excellent tumor reducing effect. Most preferably, the Flt3 ligand can have the amino acid sequence set forth in SEQ ID NO: 3.

The present invention also relates to a polynucleotide encoding the fusion protein of the present invention.
The polynucleotide encodes the fusion protein of the present invention, and the E6 and E7 fusion polypeptides can be encoded from the nucleotide sequence set forth in SEQ ID NO: 4, but are not particularly limited thereto. In addition, the signal peptide can be encoded from the base sequence described in SEQ ID NO: 5, but is not particularly limited thereto. The immunopotentiating peptide can be encoded from the base sequence described in SEQ ID NO: 6, but is not particularly limited thereto.

  In addition, the polynucleotide of the present invention can be produced by chemical synthesis or genetic engineering techniques. Chemical synthesis methods are well known to those skilled in the art, and any method can be used. It can also be purchased at the request of commercial nucleic acid synthesis and providers. In the case of producing by genetic engineering techniques, for example, the nucleic acid fragments encoding the conventionally known E6 and E7 fusion polypeptides, signal peptides and immunopotentiating peptides are obtained, and the fragments are ligated in frame. can do. Methods for obtaining the above nucleic acid fragments are well known in the art, and those skilled in the art can easily link them using appropriate restriction enzymes. In a specific implementation of the present invention, a method of manufacturing by chemical synthesis is disclosed.

The present invention also relates to a recombinant vector comprising the polynucleotide of the present invention.
In the present invention, “vector” refers to a gene product containing external DNA inserted into the genome encoding a polypeptide. In the vector related to the present invention, a secretory signal sequence, a nucleic acid sequence encoding an E6 and E7 fusion polypeptide in which the three-dimensional structure of human papillomavirus is modified, a nucleic acid sequence encoding an immunopotentiating peptide, and the like are inserted into the genome. Examples of these vectors include plasmid vectors, cosmid vectors, bacteriophage vectors, yeast vectors, and viral vectors such as adenovirus vectors, retrovirus vectors, and adeno-linked virus vectors.

  The secretory signal sequence is a nucleic acid sequence that encodes a peptide that secretes a tumor antigen expressed in a cell outside the cell and allows an immune cell to recognize it. For example, tPA, HSV gDs, Or there is a secretion signal sequence of growth hormone. Preferably, a secretory signal sequence used in higher eukaryotic cells including mammals and the like can be used, and more preferably, tPA (tissue plasma activation) can be used. Most preferably, it can have the base sequence set forth in SEQ ID NO: 5. In addition, the secretory signal sequence of the present invention can be used by substituting with a codon having high expression frequency in the host cell.

  The nucleic acid sequence encoding the immune enhancing peptide refers to a nucleic acid sequence encoding a peptide that activates cells (eg, dendritic cells) involved in the immune response to increase the immune response. As the immune enhancing peptide, CD40 ligand, Flt3 ligand, Flagellin, OX40, or the like can be used. More preferably, Flt3 ligand can be used as the immunopotentiating peptide. In addition, the nucleic acid sequence encoding the immunopotentiating peptide of the present invention can be used by substituting it with a codon having a high expression frequency in the host cell.

  In addition, the polynucleotide contained in the recombinant vector of the present invention can be replaced with a codon having high expression frequency in the host cell. As used herein, “replaced with a codon that is frequently expressed in a host cell” or “codon optimization” means that DNA is transcribed into a protein and translated in a host cell. Sometimes, there are codons with high preference depending on the host between codons directing amino acids, but by replacing these codons with high preference, the expression efficiency of the amino acid or protein encoded by the nucleic acid is increased. Say.

  Here, the “host cell” includes a prokaryotic or eukaryotic cell, and the eukaryotic cell includes not only lower eukaryotic cells including fungi and yeast, but also higher eukaryotic cells including mammals and the like. .

  The recombinant vector of the present invention can contain a nucleic acid encoding the fusion protein in a form suitable for expression of the nucleic acid encoding the fusion protein of the present invention in a host cell. That is, the recombinant vector of the present invention includes one or more regulatory sequences selected based on the host cell used for expression, which are operably linked to the nucleic acid sequence to be expressed.

  “Operably linked” refers to the regulatory sequence in a manner that allows the nucleotide sequence of interest (eg, in an in vitro transcription / translation system or in a host cell) to be expressed. It means that it is connected.

  The term “regulatory sequence” is meant to include promoters, enhancers and other regulatory elements (eg, polyadenylation signals). Regulatory sequences are instructed so that the nucleic acid of interest can be constitutively expressed in many host cells and instructed so that the nucleic acid of interest can be expressed only in a particular host cell (eg, a set Job-specific regulatory sequences). One skilled in the art can appreciate that the design of an expression vector can vary depending on factors such as the choice of host cells to be transformed and the level of protein expression desired. The expression vector of the present invention can be introduced into a host cell to express the fusion protein.

  The vectors of the present invention can also be produced, for example, by standard recombinant DNA techniques, which include, for example, blunt end and cohesive end ligation, restriction enzymes to provide suitable ends. Treatment, removal of phosphate groups by alkaline phosphatase treatment to prevent incompatible binding, enzymatic ligation with T4 DNA ligase and the like are included. DNA encoding the signal peptide obtained by chemical synthesis or genetic recombination techniques, DNA encoding the fusion polypeptide of human papillomavirus E6 and E7, and DNA encoding the immunopotentiating peptide include appropriate regulatory sequences The vector of the present invention can be produced by recombination with the vector. The vector containing the regulatory sequence can be purchased or manufactured commercially. In the present invention, pGX27, which is a DNA vaccine production vector, was produced and used.

  In one aspect, the recombinant vector of the present invention can be used to produce cells for producing the fusion protein of the present invention, pharmacology administered into an individual as a vector for gene transfer in gene therapy or as such. Can be used as an active ingredient.

The invention also relates to host cells transformed with the vectors of the invention.
The type of the host cell is as described above.

For transformation, known methods for introducing nucleic acids into organisms, cells, tissues or organs can be used, and selectable techniques that are compatible with the host cell within the range that can be understood by those skilled in the art. Can be done. Such methods include electroporation gene electroporation, protoplast fusion, calcium phosphate (CaPO ₄ ) precipitation, calcium chloride (CaCl ₂ ) precipitation, agitation with silicon carbide fibers, Agrobacterium-mediated transformation , PEG, dextran sulfate, lipofectamine, and the like.

  The invention also relates to a method of culturing the transformed host cell of the invention and expressing the fusion protein of the invention.

  The fusion protein of the present invention is easily expressed and mass-produced by culturing transformed host cells in an appropriate medium, or by introducing the transformed host cells into any animal and culturing in vivo. be able to.

  The present invention also provides an individual human papilloma comprising, as an active ingredient, one or more selected from the group consisting of the fusion protein of the present invention, a host cell transformed with a recombinant vector expressing the protein, and a disrupted product thereof. The present invention relates to a composition for preventing or treating a disease caused by a virus.

  In the present invention, the “individual” includes mammals such as humans, monkeys, mice, pigs, cows and rabbits, but is not limited to these examples.

  In addition, the disease induced by the virus can include cervical cancer, condyloma, mole, and the like.

  The composition of the present invention may further contain a pharmaceutically acceptable carrier. The above carriers include lactose, sucrose, sucrose, sorbitol, mannitol, starch, acacia gum, alginate, gelatin, calcium phosphate, calcium silicate, cellulose, methylcellulose, microcrystalline cellulose, polyvinylpyrrolidone, water, methylhydroxybenzoate, propylhydroxybenzoate , Talc, magnesium stearate and mineral oil. The composition may further include a lubricant, a wetting agent, a flavoring agent, an emulsifier, a preservative, and the like.

  The compositions of the present invention can be directly applied to an individual by any means such as, for example, intravenous, intramuscular, oral, transdermal, mucosal, intranasal, intratracheal or subcutaneous administration. However, it is not limited to these methods. The composition of the present invention can be administered to cells cultured in vitro, and can be indirectly administered to an individual by administering the cultured cells into the body. The compositions of the invention can be administered systemically or locally.

  The composition of the present invention can be formulated in oral preparations such as granules, powders, solutions, tablets, capsules, or dry syrups, or parenteral dosage forms such as injections. The dosage form is not limited. Preferably, the composition of the present invention can be in the form of a solution or an injection.

  As an active ingredient, an effective amount of the fusion protein of the present invention, or recombinant expression vector can be about 0.05 to 500 mg / kg body weight, preferably 0.5 to 50 mg / kg body weight, Dosage and allocated dose can be considered. However, the amount of active ingredient to be administered must be determined taking into account various factors such as the condition being treated, the age and weight of the patient, the severity of symptoms, and is therefore limited to the aforementioned range. is not.

  The present invention also relates to a method for preventing or treating a disease caused by human papillomavirus in an individual, comprising administering to the individual an effective amount of the composition of the present invention.

  The contents relating to the pharmaceutical composition of the present invention, its efficacy, administration method, dosage and the like are as described above.

  In the method of the present invention, the individual includes mammals such as humans, monkeys, mice, pigs, cows and rabbits, but is not limited to these examples.

  Moreover, the disease induced by the virus can include cervical cancer, condyloma, mole, and the like.

  Hereinafter, the present invention will be described in more detail through examples according to the present invention and comparative examples not according to the present invention, but the scope of the present invention is not limited to the examples presented below.

<Example 1> Construction of GX-188E DNA Abbreviations used in the examples of the present invention are defined as follows. The optimized nucleic acid sequence, “tPa” or “t” is the secretory signal sequence of the tissue plasminogen activator, “F” or “Flt3L” is the fms-like tyrosine kine 3 means ligand.

  The codon optimized tPa secretion signal sequence having the nucleic acid sequence of SEQ ID NO: 5 and the codon optimized Flt3L having the nucleic acid sequence of SEQ ID NO: 6 were chemically synthesized in a linked form. To facilitate insertion into the vector, KpnI (5 ') and NheI (3') sites were added to the ends. After treating pGX10 (Korean Patent Publication No. 2003-0047667), which is a DNA vaccine production vector, with KpnI and NheI restriction enzyme, the synthesized tPa-Flt3L was ligated with ligase to produce pGX10 / tF.

  Codon-optimized nucleic acid sequence that encodes amino acids 1 to 85 of HPV16 E6, codon-optimized nucleic acid sequence that encodes amino acids 1 to 65 of HPV16 E7, 71st amino acid of HPV16 E6 Codon-optimized nucleic acid sequence that encodes amino acids 158 to 158, codon-optimized nucleic acid sequence that encodes amino acids 51 to 98 of HPV16 E7, and amino acids 1 to 85 of HPV18 E6 Codon-optimized nucleic acid sequence, codon-optimized nucleic acid sequence encoding amino acids 1 to 65 of HPV18 E7, codon-optimized encoding amino acids 71 to 158 of HPV18 E6 Nucleic acid sequence, amino acids 51 to 105 of HPV18 E7 Were chemically synthesized in the form linked to a nucleic acid sequence that is codon-optimized for encryption (hereinafter, 16E6N16E7N16E6C16E7C18E6N18E7N18E6C18E7C: SEQ ID NO: 4). In order to facilitate insertion into the vector, NheI (5 ') and XbaI (3') sites were added to the ends. After treating pGX10 / tF with NheI and XbaI enzymes, the synthesized 16E6N16E7N16E6C16E7C18E6N18E7N18E6C18E7C was ligated with ligase to produce pGX10 / tF16E6N16E7N16E6C16E7C18E6N18E7N. The pGX10 / TF16E6N16E7N16E6C16E7C18E6N18E7N18E6C18E7C was treated with KpnI and XbaI enzymes (enzyme), to separate the TF16E6N16E7N16E6C16E7C18E6N18E7N18E6C18E7C, after the pGX10 was treated with KpnI and XbaI enzymes and ligated with a ligase, pGX27 / tF16E6N16E7N16E6C16E7C18E6N18E7N18E6C18E7C (hereinafter, referred to as "GX-188e") the Manufactured.

<Example 2> Confirmation of therapeutic effect of GX-188E on cervical cancer In order to confirm the therapeutic effect of GX-188E on cervical cancer, TC-1 tumor cells 5 × 10 ⁵ cells were subcutaneously injected into murine C57BL / 6. On the third day and the eighth day, intramuscular injection was performed in amounts of 50 μg and 100 μg, and then electroporation was performed. The volume change of the tumor cells was observed from the day when the tumor cells were injected until the 27th day. On the 36th day, the mouse spleen was removed, and 5 μg / mL anti-mouse IFN-γ antibody (BD (Pharmigen, Sandiego, Calif.) 1 × 10 ⁶ cells on plates coated with 50 μL of IL-2 and HPV16 E6 CD8 T cell antigenic determinant (epitope) (E6 _48-57 ; EVYDFAFRDL, Peptron, Korea) or HPV8 E 7 T cell antigen determinant _{(epitope) (E7 49-57; RAHYNIVTF} , Peptron, Korea) or HPV18 E6 peptide pool (peptide pool) or HPV18 E7 peptide pools (peptide pool) an Put, 37 ℃ 5% CO ₂ incubator (Froma, Minnesota, USA) were cultured for 24 hours. After the plate was washed with PBST, 2 μg / mL of IFN-γ detection antibody (BD Pharmigen, Sandiego, Calif.) With biotin was added in an amount of 50 μL, and incubated at room temperature for about 3 hours. Then, it wash | cleaned by PBST, streptavidin-AKP (alkaline phosphate) was diluted 1: 2000, 50 microliters was added, and it culture | cultivated at normal temperature for 1 hour. After washing with PBST, 66 μL of NBT (Promega, Madison, WT) and 33 μL of BCIP (Promega, Madison, WT) were added per 10 mL of alkaline phosphate buffer, and 50 μL each was added to react. I let you. In order to make the color due to the reaction appear well, the mixture was placed in a 37 ° C. incubator for about 30 minutes, then washed with sterilized water (DW), and the number of spots generated was read with a reader.

  Specific for HPV16 E6, E7 and HPV18 E6, E7 using HPV16 E6 CD8 T cell antigen determinant (epitope), HPV16 E7 CD8 T cell antigen determinant (epitope), HPV18 E6 peptide pool, HPV18 E7 peptide pool As a result of measuring the T cell immune response by ELISPOT, it was confirmed that GX-188E induces a high antigen-specific immune response and simultaneously induces a specific immune response against E6 and E7 of HPV16 and HPV18. (See FIG. 1, FIG. 2, FIG. 3 and FIG. 4).

  In mice subjected to immunotherapy against TC-1 tumor cells with GX-188E, it was possible to confirm a marked decrease in tumor volume compared to mice injected with pGX27 as a control group (see FIG. 5).

  The fusion protein of the present invention can be used as a therapeutic agent for tumors induced by HPV.

Claims (17)

A fusion polypeptide derived from human papillomavirus types 16 and 18, having the amino acid sequence set forth in SEQ ID NO: 1 and having a modified three-dimensional structure of E6 and E7;
A signal peptide for secretion of the polypeptide;
And a fusion protein comprising an immunopotentiating peptide.   The fusion protein according to claim 1, wherein the signal peptide is one or more selected from the group consisting of tPa, HSV gDs and a growth hormone secretion signal peptide.   The fusion protein according to claim 1, wherein the signal peptide has the amino acid sequence set forth in SEQ ID NO: 2.   The fusion protein according to claim 1, wherein the immunopotentiating peptide is one or more selected from the group consisting of CD40 ligand, Flt3 ligand (fms-like tyrosine kinase 3 ligand), flagellin, and OX40.   The fusion protein according to claim 1, wherein the immune enhancing peptide has the amino acid sequence set forth in SEQ ID NO: 3.   A polynucleotide encoding the fusion protein of claim 1.   The polynucleotide of Claim 6 comprising the base sequence set forth in SEQ ID NO: 4 that encodes a fusion polypeptide of human papillomavirus E6 and E7.   The polynucleotide of Claim 6 comprising the base sequence set forth in SEQ ID NO: 5 that encodes a signal peptide.   The polynucleotide of Claim 6 comprising the base sequence set forth in SEQ ID NO: 6 that encodes an immunopotentiating peptide.   A recombinant vector comprising the polynucleotide according to claim 6.   A host cell transformed with the recombinant vector according to claim 10.   A method for culturing the host cell of claim 11 and expressing the fusion protein of claim 1.   Induced by human papillomavirus in an individual, comprising as an active ingredient at least one selected from the group consisting of the fusion protein according to claim 1, a host cell transformed with a recombinant vector expressing the protein, and a disrupted product thereof A composition for preventing or treating a disease.   14. A composition according to claim 13, wherein the disease is cervical cancer.   14. The composition of claim 13, further comprising a pharmaceutically acceptable carrier.   A method of preventing or treating a disease caused by human papillomavirus in an individual, comprising administering an effective amount of the composition of claim 13 to the individual.   The method according to claim 16, wherein the disease is cervical cancer.

Images